Management of recent-onset sustained atrial fibrillation: Pharmacologic and nonpharmacologic strategies

Clinical Therapeutics

Volumn 36, Issue 9, 2014, Pages 1151-1159

  Lau, Dennis H ^a   Kalman, Jonathan ^b   Sanders, Prashanthan ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Antiarrhythmic drugs; Anticoagulation; Atrial fibrillation; Electrical cardioversion.

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

ALGORITHM; ANTICOAGULATION; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART RHYTHM; HUMAN; MEDICAL LITERATURE; RECENT ONSET SUSTAINED ATRIAL FIBRILLATION; RISK ASSESSMENT; THROMBOEMBOLISM; ATRIAL FIBRILLATION; COMPLICATION; PATHOPHYSIOLOGY; PATIENT CARE; PRACTICE GUIDELINE; STROKE;

ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CONTINUITY OF PATIENT CARE; ELECTRIC COUNTERSHOCK; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; STROKE;

EID: 84908641146     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.08.002     Document Type: Review

References (50)

1. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807-1824.
2. Wong CX, Brooks AG, Lau DH, et al. Factors associated with the epidemic of hospitalizations due to atrial fibrillation. Am J Cardiol. 2012;110:1496-1499.
3. Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med. 2012;172:739-741.
4. Arendts G, Krishnaraj M, Paull G, Rees D. Management of atrial fibrillation in the acute setting-findings from an Australasian survey. Heart Lung Circ. 2010;19:423-427.
5. Stiell IG, Clement CM, Brison RJ, et al. Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments. Ann Emerg Med. 2011;57:13-21.
6. Rogenstein C, Kelly AM, Mason S, et al. An international view of how recent-onset atrial fibrillation is treated in the emergency department. Acad Emerg Med. 2012;19:1255-1260.
7. Stiell IG, Macle L, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. Can J Cardiol. 2011;27:38-46.
8. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413.
9. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Mar 28. [Epub ahead of print].
10. Dell'Orfano JT, Patel H, Wolbrette DL, et al. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol. 1999;83:788-790, A10.
11. Ho KM, Sheridan DJ, Paterson T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. Heart. 2007;93:1433-1440.
12. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360-1420.
13. Airaksinen KE, Gronberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013;62:1187-1192.
14. Mahajan R, Brooks AG, Sullivan T, et al. Importance of the underlying substrate in determining thrombus location in atrial fibrillation: implications for left atrial appendage closure. Heart. 2012;98:1120-1126.
15. Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993;22:1359-1366.
16. Sanders P, Morton JB, Kistler PM, et al. Reversal of atrial mechanical dysfunction after cardioversion of atrial fibrillation: implications for the mechanisms of tachycardia-mediated atrial cardiomyopathy. Circulation. 2003;108:1976-1984.
17. Pollak A, Falk RH. Aggravation of postcardioversion atrial dysfunction by sotalol. J Am Coll Cardiol. 1995;25:665-671.
18. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351:2384-2391.
19. Biffi M, Boriani G, Bronzetti G, et al. Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. Heart. 1999;82:176-182.
20. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol. 2001;37:542-547.
21. Alboni P, Botto GL, Boriani G, et al. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. Heart. 2010;96:546-549.
22. Crijns HJ, Weijs B, Fairley AM, et al. Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study. Int J Cardiol. 2014;172:588-594.
23. Lip GY, Gitt AK, Le Heuzey JY, et al. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol. 2014;113:480-484.
24. Page RL, Kerber RE, Russell JK, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 2002;39:1956-1963.
25. Joglar JA, Hamdan MH, Ramaswamy K, et al. Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Cardiol. 2000;86:348-350.
26. Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol. 2001;38:1498-14504.
27. Kirchhof P, Eckardt L, Loh P, et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet. 2002;360:1275-1279.
28. Boriani G, Capucci A, Lenzi T, et al. Propafenone for conversion of recent-onset atrial fibrillation: a controlled comparison between oral loading dose and intravenous administration. Chest. 1995;108:355-358.
29. Crijns HJ, van Wijk LM, van Gilst WH, et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate: comparison of two regimens. Eur Heart J. 1988;9:634-638.
30. Xanthos T, Bassiakou E, Vlachos IS, et al. Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. Int J Cardiol. 2007;121:291-295.
31. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic review. Scand Cardiovasc J Suppl. 2013;47:2-10.
32. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313-321.
33. Conde D, Costabel JP, Caro M, et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol. 2013;168:2423-2425.
34. Conde D, Costabel JP, Aragon M, et al. Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation. Cardiovasc Ther. 2013;31:377-380.
35. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J. 2013;34:1041-1049.
36. Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol. 2013;167:1237-1241.
37. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123:131-136.
38. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61:1998-2006.
39. Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63:1082-1087.
40. Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol. 2011;57:160-166.
41. Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e004549.
42. Gupta A, Perera T, Ganesan A, et al. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm Electrophysiol. 2013;6:1082-1088.
43. Hendriks JM, de Wit R, Crijns HJ, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J. 2012;33:2692-2699.
44. Mitchell GF, Vasan RS, Keyes MJ, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297:709-715.
45. Conen D, Tedrow UB, Koplan BA, et al. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119:2146-2152.
46. Wong CX, Abed HS, Molaee P, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011;57:1745-1751.
47. Lau DH, Middeldorp ME, Brooks AG, et al. Aortic stiffness in lone atrial fibrillation: a novel risk factor for arrhythmia recurrence. PLoS One. 2013;8:e76776.
48. Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. Heart Rhythm. 2012;9:321-327.
49. Wyse DG, Van Gelder IC, Ellinor PT, et al. Lone atrial fibrillation: does it exist? J Am Coll Cardiol. 2014;63:1715-1723.
50. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060.